20/20 Biolabs, Inc.
20/20 Biolabs, Inc. is a U.S.-based testing laboratory company that develops and sells diagnostic and screening products and also provides laboratory testing services. Its reported business includes OneTest, BioCheck, and CLIAx, with operations centered on regulated laboratory testing and related service work.
Fiscal year 2025 · change from previous year
Development 2025–2025
Business
Share of revenueA core testing product sold to customers that appears to be the company's main revenue driver.
A legacy testing product with declining relevance after patent expiration and increased competition.
Laboratory services performed under the company's CLIA-related testing operations.
Products
Reported · share of revenue- One Test88.2 %
- Bio Check7.4 %
- CLI Ax4.4 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
The company sells to organizations and end users that need regulated testing, screening, and laboratory analysis. Reported disclosures point to fire department customers for OneTest and a CLIAx client for laboratory work, suggesting a mix of public-safety, institutional, and service-based demand. BioCheck appears to serve customers that value a specialized test product, though the product has faced competitive pressure over time.
They buy OneTest for testing needs tied to emergency-response or operational workflows.
They use CLIAx for outsourced testing and related lab services.
They continue purchasing BioCheck where the product remains in use despite competitive and patent-related pressure.
Strategy
The company’s near-term focus is to support its testing and laboratory business with additional capital, while maintaining and commercializing its product and service lines. It also appears to be using public-market access and financing transactions to fund operations and growth initiatives. Product execution, customer renewals, and the ability to keep laboratory capacity utilized are central to its strategy.
The business needs external funding to support operations, commercialization, and working capital.
OneTest is the main revenue source and customer renewals materially affect quarterly results.
CLIAx and other lab work depend on fixed laboratory infrastructure and execution quality.
Geography
20/20 Biolabs is organized as a U.S. company and the available disclosures do not provide a country-by-country revenue split. Its business is tied to U.S. regulatory and laboratory requirements, which makes domestic compliance and customer access important to operations. The company also references the possibility of introducing and marketing products in other states or countries, but no specific foreign operating base is disclosed.
Risks
The company faces concentration risk in a small number of products and customers, so timing shifts in renewals or work orders can materially affect quarterly revenue. It also has exposure to patent expiration, competition, regulatory compliance, and fixed laboratory cost absorption, which can pressure operating performance when volumes fall. Financing and dilution risk are also important because the business has relied on external capital to support operations.
A delayed renewal from a significant fire department customer materially affected OneTest revenue in the quarter.
Exposure: OneTest sales
BioCheck has been in long-term decline since patent expiration and the emergence of more direct competitors.
Exposure: BioCheck
The company has relied on equity, convertible notes, and warrants to fund operations.
Exposure: Capital structure
Laboratory expenses include fixed costs that do not fall proportionally with test volume.
Exposure: Laboratory operations
Testing laboratories must meet CLIA and other regulatory requirements that can affect operations and expansion.
Exposure: U.S. laboratory operations
Accounting
Judgemental itemsOneTest, BioCheck, and CLIAx may be recognized differently depending on delivery and service completion.
Impact: Affects quarterly revenue timing and comparability
Warrants issued with financing can require mark-to-market accounting.
Impact: Can create non-cash volatility in other income/expense
Debt issuance can generate original issue discount, issuance losses, and interest expense.
Impact: Affects reported net loss and financing costs
Laboratory overhead remains relatively stable even when test volume falls.
Impact: Can distort gross margin when revenues decline
Similar listed companies
Publicly listed companies with a comparable business focus.
Castle Biosciences, Inc
CSTL · Services-Medical Laboratories
Castle Biosciences is a U.S.-based molecular diagnostics company that develops tissue-based tests to help clinicians make treatment and diagnosis decisions in…
Biodesix, Inc
BDSX · Services-Medical Laboratories
Biodesix is a U.S.-based diagnostic solutions company focused on lung disease testing and diagnostic development services.
Virax Biolabs Group Ltd
VRAX · In Vitro & In Vivo Diagnostic Substances
Virax Biolabs Group Ltd is a Cayman Islands-based life sciences group focused on diagnostic and immunology-related products, with operating and holding…
Trinity Biotech plc
TRIB · In Vitro & In Vivo Diagnostic Substances
Trinity Biotech plc is a commercial-stage diagnostics company that develops, manufactures, and markets human diagnostic systems for point-of-care and clinical laboratory use.
Bio-Rad Laboratories, Inc
BIO · Laboratory Analytical Instruments
Bio-Rad Laboratories is a U.S.-based multinational that develops, manufactures, and sells tools used in life science research and clinical diagnostics.
BioLife Solutions, Inc
Electromedical & Electrotherapeutic Apparatus
Last updated: 11/08/2026